Leaders in Pharmaceutical Business Intelligence (LPBI) Group

4

Orthopedic and Dental

&

&

&

Telerescue.com

Gerard Loiseau

Dr. Peter Nelboeck

Dr. Williams

Aviva Lev-Ari, PhD, RN

Yoel Ezra

&

22 Israeli start ups

http://www.iati.co.il/sub-category/18/2/tissue-engineering-cell-therapy-

·       Novastis

·       J&J

·       Merck

·       Roche’s R&D spending in 2013: $10 billion. As a percentage of revenue: 19% Leading the healthcare industry in R&D spending, the Swiss biopharmaceutical company spends more today than it did when it topped the Strategy& list three years ago. The company invests an overwhelming majority of its R&D budget —almost 90%—on pharmaceuticals, while the rest goes into diagnostics. Oncology, the largest part of Roche’s business, eats about half of its pharma R&D spending. One of the company’s latest drugs, a targeted medicine for advanced breast cancer called Kadcyla, was approved in the U.S. and E.U. last year. Roche says it is looking to leverage parts of the Kadcyla platform (for instance, the innovative way it links chemotherapeutic agents and antibodies) for future drugs.

·

Stryker

Cooper

Wright Medical

ResMed Inc

Steris Corp

Sirona Dental Systems

Varian Medical Systems

CareFusion

Natus Medical

Smith & Nephew

Abbott Labs

Baxter

Johnson&Johnson

Engologix

Boston Scientific

St Jude Medical

Becton Dickson

EdwardsLS

Bard (C.R.)

http://www.fiercemedicaldevices.com/story/oxford-performance-materials-gets-fda-nod-3-d-printed-spinal-implant/2015-07-24